169 related articles for article (PubMed ID: 32362631)
21. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
22. Imaging Mass Spectrometry for the Classification of Melanoma Based on
Casadonte R; Kriegsmann M; Kriegsmann K; Streit H; Meliß RR; Müller CSL; Kriegsmann J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982192
[TBL] [Abstract][Full Text] [Related]
23. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
24. BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.
Chisholm JC; Suvada J; Dunkel IJ; Casanova M; Zhang W; Ritchie N; Choi Y; Park J; Das Thakur M; Simko S; Wan Rachel Tam N; Ferrari A
Pediatr Blood Cancer; 2018 May; 65(5):e26947. PubMed ID: 29350463
[TBL] [Abstract][Full Text] [Related]
25. Multiple eruptive squamous cell carcinomas: a possible clinical sign in melanoma patients treated with vemurafenib.
Jovic A; Tiodorovic D; Popovic D; Vidovic N; Zlatanovic Z; Cekic S; Kocic H; Damiani G
Eur J Dermatol; 2021 Apr; 31(2):279-280. PubMed ID: 34001482
[No Abstract] [Full Text] [Related]
26. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
27. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
28. Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.
Arozarena I; Goicoechea I; Erice O; Ferguson J; Margison GP; Wellbrock C
Mol Cancer; 2014 Jun; 13():154. PubMed ID: 24941944
[TBL] [Abstract][Full Text] [Related]
29. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
30. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
31. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
Dietrich P; Kuphal S; Spruss T; Hellerbrand C; Bosserhoff AK
Oncogene; 2018 Feb; 37(7):897-911. PubMed ID: 29059159
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
33. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes.
Mikhailenko DS; Efremov GD; Safronova NY; Strelnikov VV; Alekseev BY
Bull Exp Biol Med; 2017 Jan; 162(3):375-378. PubMed ID: 28091917
[TBL] [Abstract][Full Text] [Related]
34. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
35. Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications.
Mandel VD; Medri M; Manganoni AM; Pavoni L; De Rosa F; Ribero S; Foca F; Andreis D; Mazzoni L; Magi S; Farnetani F; Palla M; Ulivi P; Stanganelli I
J Dermatolog Treat; 2022 May; 33(3):1368-1375. PubMed ID: 32875931
[TBL] [Abstract][Full Text] [Related]
36. High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.
Göppner D; Müller J; Krüger S; Franke I; Gollnick H; Quist SR
Acta Derm Venereol; 2014 Sep; 94(5):517-20. PubMed ID: 24531394
[TBL] [Abstract][Full Text] [Related]
37. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
Choe CH; McArthur GA; Caro I; Kempen JH; Amaravadi RK
Am J Ophthalmol; 2014 Oct; 158(4):831-837.e2. PubMed ID: 25036880
[TBL] [Abstract][Full Text] [Related]
38. Safety of vemurafenib in patients with BRAF
Arance AM; Berrocal A; Lopez-Martin JA; de la Cruz-Merino L; Soriano V; Martín Algarra S; Alonso L; Cerezuela P; La Orden B; Espinosa E
Clin Transl Oncol; 2016 Nov; 18(11):1147-1157. PubMed ID: 26983408
[TBL] [Abstract][Full Text] [Related]
39. Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib.
Sibaud V; Chevreau C
Joint Bone Spine; 2014 Jul; 81(4):373-4. PubMed ID: 24468667
[No Abstract] [Full Text] [Related]
40. Essential Oil of
Chang CT; Soo WN; Chen YH; Shyur LF
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]